Division of Infectious Diseases, University of Louisville
Current guidelines recommend a β-lactam plus a macrolide or fluoroquinolone monotherapy as initial empiric antibiotic therapy for treatment of patients hospitalized with community-acquired pneumonia (CAP). Multiple studies have shown different results comparing the two regimens for the treatment of CAP. Our objective, in a city-wide prospective study, was to compare outcomes among hospitalized patients with CAP who received empiric treatment either with a β-lactam plus a macrolide or fluoroquinolone monotherapy.
This was a propensity score matched case-control study of the University of Louisville Pneumonia Study. It was a prospective population-based cohort study of all hospitalized adults with CAP. Patients were divided into two groups and propensity score matched based on empiric therapy; a β-lactam plus a macrolide compared to fluoroquinolone monotherapy. Study outcomes were time to clinical stability, length of stay, and in-hospital, 30-day and 1-year mortality. Stratified Cox proportional hazards regression was performed to analyze continuous variable differences between groups. Conditional logistic regression was performed to analyze dichotomous variable differences in mortality.
An association was not found between the two groups for time to clinical stability (aHR: 1.06; 95% CI: 0.93-1.22), length of stay (aHR: 1.14; 95% CI: 0.99-1.32) or mortality.
The present study did not show any difference in short or long-term outcomes for hospitalized patients with CAP who were treated with either a β-lactam plus a macrolide or fluoroquinolone monotherapy. Hence, our study does not support the superiority of one treatment over other.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Salunkhe, Vidyulata; Furmanek, Stephen P.; and Arnold, Forest W.
"Beta-lactam plus Macrolide vs Fluoroquinolone for Empiric Therapy of Hospitalized Patients with CAP: Results from the University of Louisville Pneumonia Study,"
The University of Louisville Journal of Respiratory Infections: Vol. 3
, Article 6.
Available at: https://ir.library.louisville.edu/jri/vol3/iss1/6
Community Health and Preventive Medicine Commons, Epidemiology Commons, Health Information Technology Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, International Public Health Commons, Translational Medical Research Commons